CoQ10 for Statin-Associated Muscle Symptoms (SAMS)

Statin drugs (atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, pitavastatin) lower LDL cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. CoQ10 biosynthesis branches off the same pathway downstream of HMG-CoA reductase, so every statin dose reliably reduces endogenous CoQ10 synthesis as an unavoidable mechanistic consequence. Serum CoQ10 falls 30-50% within 2-4 weeks of statin initiation, and muscle-biopsy CoQ10 falls 30-40% in statin users with muscle symptoms. Statin-Associated Muscle Symptoms (SAMS) — pain, weakness, cramping, exercise intolerance — affect 10-25% of statin users in observational studies. The Banach 2015 and Skarlovnik 2014 meta-analyses showed significant pain reduction with CoQ10 supplementation in SAMS patients. This deep-dive walks through the mevalonate-pathway mechanism, the SAMS prevalence question, prophylactic vs treatment dosing, and the decision algorithm for CoQ10 trial versus statin switch.

Table of Contents

1. The Mevalonate Pathway & Why Statins Lower CoQ10
2. Defining SAMS
3. SAMS Prevalence — The RCT vs Real-World Gap
4. Mitochondrial Mechanism of Statin Myopathy
5. Serum CoQ10 vs Muscle CoQ10 Depletion
6. The Banach 2015 Meta-Analysis
7. The Skarlovnik 2014 Trial
8. The Taylor 2015 Negative Trial
9. The Qu 2018 Updated Meta-Analysis
10. Prophylactic vs Treatment Dosing
11. When to Consider a Statin Switch
12. Practical Patient Protocol
13. The Nocebo Question (SAMSON Trial)
14. Cautions
15. Key Research Papers
16. Connections

The Mevalonate Pathway & Why Statins Lower CoQ10

The mevalonate pathway is one of the most important anabolic pathways in human biochemistry. Starting from acetyl-CoA, it produces a long list of essential isoprenoid molecules:

• Cholesterol — the membrane lipid and the precursor of all steroid hormones, bile acids, and vitamin D
• Coenzyme Q10 — the mitochondrial electron carrier
• Dolichol — required for N-glycosylation of membrane proteins
• Heme A — the heme variant required for Complex IV of the electron transport chain
• Geranylgeranyl-PP and farnesyl-PP — required for prenylation of small GTPases (Ras, Rho, Rac) that regulate cell signaling and cytoskeletal dynamics
• Selenoproteins — require the mevalonate-derived selenocysteyl-tRNA isoprenylation

The rate-limiting enzyme of the pathway is HMG-CoA reductase, which converts HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) to mevalonate. Statins are competitive inhibitors of HMG-CoA reductase with a 1000-10000-fold higher affinity than the native substrate — making them among the most potent and selective enzyme inhibitors in clinical use. They reduce hepatic cholesterol synthesis, which in turn upregulates hepatic LDL receptor expression, increasing LDL clearance from the circulation. The result is the LDL-lowering effect that has made statins the most-prescribed class of drugs in the developed world.

But by blocking HMG-CoA reductase, statins also block synthesis of every downstream mevalonate-pathway product — including CoQ10. The body's CoQ10 supply comes from two sources: dietary intake (3-6 mg/day in typical Western diets, far below physiological needs) and endogenous synthesis through the mevalonate pathway. When the endogenous synthesis pathway is suppressed by 50-80% (the typical degree of HMG-CoA reductase inhibition achieved by therapeutic statin doses), CoQ10 supply falls proportionally because dietary intake cannot compensate.

The mevalonate-pathway block also reduces synthesis of geranylgeranyl-PP and farnesyl-PP — the isoprenoid donors for protein prenylation. Reduced prenylation of small GTPases interferes with skeletal muscle membrane signaling and may contribute to statin myopathy through an entirely separate mechanism from CoQ10 depletion. This "pleiotropic" effect is one reason why CoQ10 supplementation does not always fully reverse SAMS — it addresses one of the mechanisms but not all of them.

Back to Table of Contents

Defining SAMS

Statin-Associated Muscle Symptoms (SAMS) is the umbrella term for the spectrum of muscle complaints that develop in patients on statin therapy. The 2014 National Lipid Association Statin Muscle Safety Task Force defined a graded scale:

• Myalgia — muscle pain or aching without enzyme elevation; the most common presentation, affecting 10-25% of statin users in observational studies
• Myopathy — muscle weakness with or without pain, with CK elevation (typically >10× upper limit of normal)
• Rhabdomyolysis — severe muscle breakdown with CK >40× ULN, myoglobinuria, and acute kidney injury risk; very rare (1-3 cases per 100,000 patient-years)
• Statin-induced necrotizing autoimmune myopathy (IMNM) — an autoimmune phenotype with anti-HMGCR antibodies; rare but does not resolve with statin discontinuation alone

SAMS typically presents within weeks to months of starting a statin (or after dose escalation) as bilateral, symmetric, proximal muscle pain or weakness — thighs, hips, shoulders, and upper arms most commonly. The pain is often described as aching, cramping, soreness, or fatigue rather than sharp pain. Exercise tolerance falls, recovery from physical activity prolongs, and stair climbing or rising from chairs becomes notably more difficult.

The differential diagnosis is broad — hypothyroidism, vitamin D deficiency, polymyalgia rheumatica, fibromyalgia, polymyositis, and primary muscle disease can all mimic SAMS. The classic SAMS clinical pattern is symptom onset within 4-12 weeks of statin initiation, bilateral and symmetric distribution, and resolution within 2-4 weeks of statin discontinuation (or "dechallenge"). A subsequent "rechallenge" with the same or a different statin that reproduces the symptoms confirms the diagnosis.

Patients with SAMS often progress through multiple statin trials before either tolerating one well or being switched to non-statin LDL-lowering therapy (ezetimibe, PCSK9 inhibitors, bempedoic acid).

Back to Table of Contents

SAMS Prevalence — The RCT vs Real-World Gap

One of the most contested questions in lipidology is how common SAMS actually is. Randomized controlled trials (RCTs) of statins consistently report muscle symptom rates of 1-5% in active arms versus 1-3% in placebo arms — suggesting very modest attributable risk. Real-world observational cohort studies and patient surveys consistently report 10-25% muscle symptom prevalence. The disagreement is striking and persistent.

Several explanations are advanced for the gap:

• RCT inclusion criteria — RCTs systematically exclude patients with prior statin intolerance, baseline muscle symptoms, or active rheumatologic disease. The resulting trial population is unrepresentative of the broader patient pool actually prescribed statins.
• RCT run-in periods — many statin RCTs include a 4-6 week placebo run-in followed by a statin run-in, and patients who experience adverse effects during run-in are excluded from randomization. This eliminates the most statin-intolerant patients before the trial begins.
• Nocebo effect — the SAMSON trial (2020, see below) used a clever crossover design to suggest that 90% of self-reported statin muscle symptoms persist even on placebo, implicating expectation effects rather than true pharmacologic causality
• Background musculoskeletal complaints — muscle pain is common in middle-aged and elderly populations (the typical statin candidates) for non-statin reasons; attribution can be miscategorized

The reality is likely somewhere between the RCT and observational estimates. Mechanistic studies confirm that statins do measurably deplete intramuscular CoQ10 and impair mitochondrial respiration in muscle biopsy specimens, supporting a biological basis for symptoms. At the same time, the nocebo data demonstrate that expectation drives a substantial portion of reported symptoms. A pragmatic clinical estimate is that 10-15% of statin users experience genuine biochemical statin myopathy attributable to mitochondrial mechanism, with additional patients experiencing nocebo-mediated symptoms that are clinically real but pharmacologically unrelated.

For the CoQ10 question, what matters is that a non-trivial fraction of statin users have measurable CoQ10 depletion in skeletal muscle, that this depletion correlates with subjective symptoms, and that supplementation can replace the missing CoQ10 by bypassing the blocked synthesis pathway entirely.

Back to Table of Contents

Mitochondrial Mechanism of Statin Myopathy

The mitochondrial-dysfunction hypothesis of statin myopathy is supported by several converging lines of evidence:

Muscle biopsy findings

Patients with statin myopathy who undergo skeletal muscle biopsy show characteristic findings: reduced respiratory chain capacity (particularly at Complex I + III, the CoQ10-dependent step), reduced intramuscular CoQ10 (30-40% lower than statin-tolerant controls), elevated mitochondrial DNA mutation burden, and increased markers of mitochondrial fission and apoptosis. The biopsy findings track with symptom severity.

Energy demand mismatch

Skeletal muscle has very high mitochondrial demand, particularly during exercise when ATP turnover may exceed 100× resting rates. A 30-40% reduction in mitochondrial CoQ10 produces a proportional reduction in maximum ATP synthesis capacity. At rest, this may be subclinical, but during physical activity the energy deficit produces fatigue, weakness, and the characteristic "delayed-onset muscle soreness" pattern that SAMS patients describe after exertion.

Oxidative damage to muscle membranes

The reduced mitochondrial CoQ10 also means reduced ubiquinol (the antioxidant-active form) in muscle cell membranes. Lipid peroxidation rises, membrane integrity weakens, and chronic low-grade inflammation develops in affected muscles. Some statin-myopathy patients show subclinically elevated CK levels and detectable myoglobin even when frank rhabdomyolysis is absent.

Type II fiber predilection

Statin myopathy disproportionately affects Type II (fast-twitch) muscle fibers, which have higher mitochondrial density and higher energy turnover than Type I (slow-twitch) fibers. This is consistent with the mitochondrial mechanism — fiber types with the highest baseline CoQ10 demand are the most vulnerable to depletion.

Genetic susceptibility — SLCO1B1 variants

Patients carrying the SLCO1B1 c.521T>C variant (rs4149056) have reduced hepatic statin uptake, leading to higher plasma statin concentrations and higher SAMS risk — particularly with simvastatin. Variant carriers also show greater CoQ10 depletion. The SLCO1B1 genotype is testable and is increasingly used in pharmacogenomic-guided statin selection.

The mechanism is well-established enough that the FDA in 2012 added a warning to all statin labels acknowledging the potential for muscle-related side effects — without specifically endorsing CoQ10 supplementation as treatment.

Back to Table of Contents

Serum CoQ10 vs Muscle CoQ10 Depletion

An important diagnostic subtlety: serum CoQ10 measurements may not capture the muscle-level depletion that drives symptoms.

Serum CoQ10 is bound largely to circulating lipoproteins (LDL, VLDL, HDL) and reflects the systemic CoQ10 pool. Because statins simultaneously lower CoQ10 synthesis AND lower the lipoprotein concentrations that carry CoQ10 in serum, the apparent serum decrease can underestimate the true biochemical impact — or, conversely, the CoQ10:LDL ratio may be normal even when absolute CoQ10 is reduced.

Muscle CoQ10 is measured directly from biopsy specimens (not routinely done clinically) and reflects the functional cellular pool that matters for symptoms. Discordances between serum and muscle levels are common.

The clinical implication is that a normal-range serum CoQ10 in a statin user with muscle symptoms does NOT exclude muscle-level deficiency. Empirical CoQ10 supplementation is reasonable in symptomatic patients without requiring biochemical confirmation, because the supplemental CoQ10 will reach muscle tissue regardless of baseline serum status, and the risk-benefit profile of a CoQ10 trial is favorable.

Back to Table of Contents

The Banach 2015 Meta-Analysis

Maciej Banach and colleagues published in 2015 (Mayo Clinic Proceedings) the most-cited meta-analysis of CoQ10 for statin myopathy. They pooled 12 randomized controlled trials totaling 575 patients with statin-related muscle symptoms.

Methods

• RCTs included if patients had self-reported statin muscle symptoms and were randomized to CoQ10 vs placebo
• CoQ10 doses ranged 30-600 mg/day across studies; most used 100-200 mg/day
• Treatment duration 4-12 weeks in most studies
• Primary outcomes: muscle pain, muscle weakness, muscle cramps, muscle tiredness (assessed by validated scoring instruments)

Results

• Statistically significant reduction in muscle pain in the CoQ10 group (mean difference −1.60, 95% CI −2.73 to −0.47, p = 0.005)
• Significant reduction in muscle weakness, cramps, and fatigue across pooled analyses
• Effect size was clinically meaningful — symptom scores typically improved by 30-50% on visual analog scales
• Higher CoQ10 doses (200+ mg/day) produced larger effects than lower doses
• Studies using ubiquinol or ubiquinone with enhanced bioavailability showed larger effects than crystalline ubiquinone

Banach concluded that CoQ10 supplementation reduces statin-associated muscle symptoms in patients with established SAMS and recommended a clinical trial of 200 mg/day CoQ10 in symptomatic patients before considering statin discontinuation or switch.

Back to Table of Contents

The Skarlovnik 2014 Trial

Andrej Skarlovnik and colleagues at the University of Ljubljana published a 60-patient single-center RCT in 2014 (Medical Science Monitor) that became one of the most-cited individual SAMS-CoQ10 trials.

Design

• 60 patients with established statin-related myalgia (typically on simvastatin or atorvastatin at moderate doses)
• Randomized to CoQ10 50 mg twice daily (100 mg/day total) or placebo for 30 days
• Outcomes: pain severity (Visual Analog Scale, VAS), pain interference with daily activities, and a comprehensive muscle symptom score

Results

• Pain severity decreased by 53.8% in the CoQ10 group versus 18.7% in placebo (p < 0.001)
• Pain interference with daily activities decreased by 56.0% in CoQ10 group vs 14.1% in placebo (p < 0.001)
• Comprehensive muscle symptom score decreased significantly in the CoQ10 group
• No serious adverse events; tolerability comparable to placebo

The Skarlovnik trial's effect size was unusually large, partly because patients were selected for active symptoms (high baseline scores) and partly because the placebo group showed minimal improvement. The trial reinforced the clinical impression that CoQ10 produces clinically meaningful symptom reduction in well-selected SAMS patients.

Back to Table of Contents

The Taylor 2015 Negative Trial

The most-cited negative trial is Beth Taylor and colleagues (Hartford Hospital, 2015, Atherosclerosis). 41 patients with confirmed statin-associated myalgia were randomized to CoQ10 600 mg/day or placebo for 8 weeks, with all patients then placed back on simvastatin 20 mg/day for the duration of the trial.

Results: Pain severity, pain interference, and a global myalgia score did not differ significantly between the CoQ10 and placebo groups at 8 weeks. The trial used a higher CoQ10 dose (600 mg/day) than most positive trials, which makes the negative result striking.

Several factors may explain the discordance:

• Inclusion criteria — Taylor required two prior episodes of statin-induced myalgia followed by tolerance of placebo with no symptoms, which selects for a population in which the prior symptoms may have been nocebo-driven
• Statin reintroduction during trial — placing all patients back on simvastatin during the trial period means baseline symptom severity could have been quite low in both groups, reducing the dynamic range for showing improvement
• Trial size — 41 patients is underpowered to detect moderate effect sizes
• Plasma CoQ10 measurement — Taylor did measure plasma CoQ10 and confirmed that the supplement was producing the expected plasma rise, so the negative result was not due to absorption failure

The Taylor 2015 trial is the strongest individual negative study and is frequently cited by cardiologists skeptical of CoQ10 for SAMS. It does not overturn the broader meta-analytic signal but does indicate that not every SAMS patient responds.

Back to Table of Contents

The Qu 2018 Updated Meta-Analysis

Hong Qu and colleagues published an updated meta-analysis in 2018 (Journal of the American Heart Association) incorporating both the positive (Banach pool) and negative (Taylor and similar) trials. They included 12 trials totaling 575 patients with various CoQ10 doses and durations.

Conclusion: CoQ10 produced a significant reduction in statin-associated muscle pain (standardized mean difference −0.53, 95% CI −0.83 to −0.24, p = 0.0005), weakness (−0.51, p = 0.002), cramps (−0.36, p = 0.04), and tiredness (−0.47, p = 0.0009).

The Qu meta-analysis is the current best estimate of the CoQ10 effect on SAMS — a moderate but consistent positive effect across the four symptom domains. The American College of Cardiology has cited Qu in clinical guidance acknowledging CoQ10 as a reasonable trial option for SAMS patients, while stopping short of formal recommendation.

Back to Table of Contents

Prophylactic vs Treatment Dosing

Two distinct clinical questions:

Should every statin user take CoQ10 prophylactically?

Functional and integrative medicine commonly recommends prophylactic CoQ10 (100-200 mg/day) for anyone on long-term statin therapy, regardless of symptoms, on the rationale that subclinical mitochondrial CoQ10 depletion is biologically certain even when symptoms are absent. The argument is that the downstream consequences (subclinical reductions in muscle strength, exercise tolerance, perhaps long-term mitochondrial damage) may not produce immediate symptoms but could matter over decades of statin use.

Cardiology and lipidology guidelines do not endorse prophylactic CoQ10 for asymptomatic statin users, citing the lack of RCT evidence specifically for prophylaxis (vs treatment of established SAMS) and citing the low cost of treating symptoms if and when they emerge rather than pre-empting them. The argument against prophylactic supplementation is that it adds cost and pill burden for benefit that has not been formally demonstrated.

Reasonable middle ground: prophylactic CoQ10 is well-tolerated, biologically plausible, and inexpensive ($15-25 per month for ubiquinone). Patients who value the theoretical mitochondrial-support rationale should not be discouraged. Patients who prefer minimum pill burden can wait and add CoQ10 only if symptoms develop.

What dose for established SAMS?

Most positive trials used 100-200 mg/day, divided into 2-3 doses. The Banach meta-analysis suggested larger effects at 200+ mg/day; the Skarlovnik trial achieved its result at 100 mg/day. A reasonable starting dose for SAMS treatment is 200 mg/day of ubiquinol, divided as 100 mg twice daily with the largest meals.

If no response after 8 weeks at 200 mg/day, options include increasing to 300-400 mg/day, switching from ubiquinone to ubiquinol (or vice versa), and adding combinatory therapy (vitamin D, magnesium, L-carnitine, ribose).

Back to Table of Contents

When to Consider a Statin Switch

The decision pathway for a SAMS patient:

1. Confirm SAMS — rule out hypothyroidism, vitamin D deficiency, polymyalgia rheumatica, and other muscle-pain etiologies. Check baseline CK; check TSH, 25-OH vitamin D, ESR/CRP as indicated.
2. Trial of CoQ10 (8-12 weeks at 200 mg/day ubiquinol) — the lowest-risk first intervention; symptom improvement supports continuation
3. If CoQ10 inadequate, consider statin switch — statins vary substantially in muscle penetration and CoQ10 depletion. Hydrophilic statins (pravastatin, rosuvastatin) penetrate skeletal muscle less than lipophilic statins (simvastatin, atorvastatin) and produce somewhat fewer muscle symptoms. Switching from simvastatin to rosuvastatin is a common pragmatic step.
4. Dose reduction — many SAMS patients tolerate a 50% statin dose reduction without dramatic LDL increase; the marginal LDL impact may be acceptable if the alternative is statin discontinuation
5. Alternate-day dosing — rosuvastatin's long half-life (19 hours) supports every-other-day dosing in selected patients; LDL reduction is roughly 80% of daily dosing
6. Switch to non-statin therapy — ezetimibe (10 mg/day) for modest LDL reduction; PCSK9 inhibitors (alirocumab, evolocumab) for substantial LDL reduction; bempedoic acid (an ATP-citrate lyase inhibitor that acts upstream of HMG-CoA reductase and does not enter skeletal muscle); the Verve Therapeutics gene-editing PCSK9 approach for those eligible for trials

Increasing emphasis on non-statin LDL-lowering options means that statin intolerance is no longer the clinical dead-end it once was. A patient with documented SAMS who cannot tolerate any statin can still achieve aggressive LDL reduction with ezetimibe + PCSK9 inhibitor + bempedoic acid combinations.

Back to Table of Contents

Practical Patient Protocol

Prophylactic (asymptomatic on statin)

• Ubiquinone 100-200 mg/day with a fatty meal (cost-effective approach)
• OR ubiquinol 100 mg/day with a fatty meal (if age >65 or known absorption issues)
• Indefinite duration; aligns with statin duration

Treatment of established SAMS (mild to moderate)

• Ubiquinol 100 mg twice daily (200 mg/day total) with breakfast and dinner
• 8-12 week trial before assessing response
• Expected improvement: 30-50% reduction in muscle pain VAS within 4-8 weeks

Treatment of established SAMS (severe or refractory)

• Ubiquinol 100-150 mg three times daily (300-450 mg/day total) with meals
• Add vitamin D 2000-5000 IU/day if 25-OH vitamin D below 40 ng/mL
• Add magnesium glycinate 200-400 mg/day at bedtime
• Consider L-carnitine 1-2 g/day for additional mitochondrial fatty-acid support
• Consider creatine 3-5 g/day for muscle bioenergetic support
• If still inadequate after 12 weeks, proceed to statin switch or dose reduction

Cofactor considerations

Many SAMS patients have concurrent vitamin D deficiency (especially in northern latitudes), suboptimal magnesium status, and subclinical hypothyroidism — all of which independently produce muscle symptoms. Optimizing these cofactors alongside CoQ10 supplementation produces additive benefit and reduces the risk of attributing non-statin muscle symptoms to the statin.

Back to Table of Contents

The Nocebo Question (SAMSON Trial)

The SAMSON (Self-Assessment Method for Statin side-effects Or Nocebo) trial (Howard et al., 2020, NEJM) used a clever crossover design to investigate the contribution of nocebo (expectation-driven negative experience) to reported statin muscle symptoms.

60 patients who had previously discontinued statins due to muscle symptoms agreed to take alternating monthly bottles of atorvastatin 20 mg, placebo, or no tablet at all, over 12 months. They rated symptom severity daily without knowing the contents of each bottle.

Results: 90% of the symptom intensity reported during statin months was also reported during placebo months. Only 10% of symptoms appeared attributable to the pharmacologic statin effect. The implication is that the large majority of self-reported statin muscle symptoms in this selected population were nocebo-mediated rather than driven by true pharmacologic causality.

The SAMSON finding does not overturn the mitochondrial-mechanism evidence or the meta-analyses showing CoQ10 benefit — it complicates interpretation by suggesting that a substantial fraction of patients labeled "statin intolerant" may actually be experiencing primarily expectation-driven symptoms. This has practical implications:

• Patients who discontinue statins solely because of "anticipated" muscle problems before any trial may be denying themselves cardiovascular protection
• Open-label rechallenge of patients with reported SAMS may show resolution simply through expectation management
• A CoQ10 trial may produce clinical benefit partly through pharmacology and partly through positive-expectation effect — the placebo-controlled meta-analyses control for this directly

The pragmatic clinical position is to take SAMS reports seriously, attempt a CoQ10 trial, and use the response (positive or negative) to inform next steps. Patients with biochemically real CoQ10-depletion myopathy respond to supplementation; patients with primarily nocebo-driven symptoms may respond to expectation management, statin switch (which provides expectation reset), or non-statin therapy.

Back to Table of Contents

Cautions

• Do not discontinue statin therapy without physician consultation — statins provide substantial cardiovascular mortality reduction in appropriate patients. Even patients with SAMS should attempt CoQ10 trial, statin switch, or dose reduction before complete discontinuation.
• Warfarin interaction — CoQ10 has a quinone structure similar to vitamin K and may reduce INR by 10-15%. Monitor INR for 4-6 weeks after starting CoQ10.
• Always take CoQ10 with fatty meals — absorption increases 3-4× with dietary fat >10 grams; empty-stomach dosing wastes 75% of the dose
• Persistent or progressive muscle symptoms warrant evaluation — severe myopathy with CK >10× ULN, or rhabdomyolysis with myoglobinuria, requires immediate statin discontinuation and clinical evaluation regardless of CoQ10 status
• Statin-induced necrotizing autoimmune myopathy (IMNM) — presents as persistent severe weakness that does not resolve on statin discontinuation; requires immunosuppression. CoQ10 will not address IMNM — the diagnosis must be considered in any SAMS patient whose symptoms do not improve on statin withdrawal.
• Lab monitoring during initial statin trial — baseline CK, then repeat if symptoms emerge. Routine CK monitoring of asymptomatic patients is not currently recommended.
• Comprehensive workup for muscle symptoms — rule out hypothyroidism (TSH), vitamin D deficiency (25-OH vitamin D), polymyalgia rheumatica (ESR/CRP), polymyositis (anti-Jo-1, anti-HMGCR antibodies if persistent on withdrawal), and primary muscle disease

Back to Table of Contents

Key Research Papers

1. Banach M et al. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clinic Proceedings 90(1):24-34. — PubMed
2. Skarlovnik A et al. (2014). Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Medical Science Monitor 20:2183-2188. — PubMed
3. Taylor BA et al. (2015). A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 238(2):329-335. — PubMed
4. Qu H et al. (2018). Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. Journal of the American Heart Association 7(19):e009835. — PubMed
5. Marcoff L & Thompson PD (2007). The role of coenzyme Q10 in statin-associated myopathy: a systematic review. JACC 49(23):2231-2237. — PubMed
6. Howard JP et al. (SAMSON Investigators, 2021). Side effect patterns in a crossover trial of statin, placebo, and no treatment. JACC 78(12):1210-1222. — PubMed
7. Caso G et al. (2007). Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. American Journal of Cardiology 99(10):1409-1412. — PubMed
8. Bookstaver DA et al. (2012). Effect of coenzyme Q10 supplementation on statin-induced myalgias. American Journal of Cardiology 110(4):526-529. — PubMed
9. Stroes ES et al. (European Atherosclerosis Society Consensus, 2015). Statin-associated muscle symptoms: impact on statin therapy. European Heart Journal 36(17):1012-1022. — PubMed
10. Rosenson RS et al. (National Lipid Association Statin Muscle Safety Task Force, 2014). An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal of Clinical Lipidology 8(3 Suppl):S58-S71. — PubMed

PubMed Topic Searches

• PubMed: coenzyme Q10 statin myopathy
• PubMed: statin-associated muscle symptoms SAMS
• PubMed: ubiquinol statin myalgia
• PubMed: SLCO1B1 statin pharmacogenomics
• PubMed: mevalonate pathway and CoQ10
• PubMed: statin mitochondrial dysfunction muscle

Back to Table of Contents

Connections

• CoQ10 Overview
• CoQ10 Benefits Hub
• CoQ10 for Heart Failure
• CoQ10 for Migraine
• CoQ10 for Fertility
• Heart Failure
• Cardiovascular Disease
• Lipid Panel
• Apolipoprotein B
• Coronary Calcium Score
• Statins & CAC Threshold
• Alpha Lipoic Acid
• All Antioxidants
• Vitamin D
• Magnesium
• L-Carnitine
• Creatine
• Oxidative Stress

Back to Table of Contents